Phaseline

Companies › EpiDestiny

EpiDestiny: clinical trials, targets and expected readouts

1 active drug program in 105 registered trials: 55 Phase 2, 46 Phase 1, 2 Phase 4, 2 Phase 3; Neurology, Hematology, Oncology, Other; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Decitabine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) …Oct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04476199DecitabinePhase 2Acute Myeloid LeukemiaOncologyFeb 2023
NCT04763928DecitabinePhase 2Acute Myeloid LeukemiaOncologyOct 2024
NCT04905810DecitabinePhase 2Acute Myeloid LeukemiaOncologyMay 2025
NCT04817241DecitabinePhase 1Acute Myeloid LeukemiaOncologyJun 2025
NCT03240211DecitabinePhase 1PTCLOncologyJul 2025
NCT05870995DecitabinePhase 2Refractory LeukemiaOncologyFeb 2026
NCT06683885DecitabinePhase 1Newly Diagnosed Diffuse Large B-cell LymphomaOncologyMay 2026
NCT02961101DecitabinePhase 1Malignancies MultipleOncologyMay 2026
NCT05089370DecitabinePhase 1Malignant MelanomaOncologyAug 2026
NCT05657639DecitabinePhase 2Acute Myeloid LeukemiaOncologyOct 2026
NCT04097470DecitabinePhase 2AML/MDSOncologyNov 2026
NCT04980404DecitabinePhase 1Myelodysplastic SyndromesOncologyNov 2026
NCT06454448DecitabinePhase 1Adebrelimab (SHR-1316)OncologyNov 2026
NCT07712848DecitabinePhase 3AML (Acute Myeloid Leukemia)OncologyDec 2026
NCT06701357DecitabinePhase 2DLBCLOncologyDec 2026
NCT04178005DecitabinePhase 4Multiple SclerosisNeurologyDec 2026
NCT07044544DecitabinePhase 1Myeloid MalignancyOncologyDec 2026
NCT05603884DecitabinePhase 2Leukemia, Myeloid, AcuteOncologyDec 2026
NCT06060782DecitabinePhase 1Burkitt LymphomaOncologyDec 2026
NCT05010772DecitabinePhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT06651866DecitabinePhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT05455294DecitabinePhase 1Myeloid MalignancyOncologyDec 2026
NCT06401603DecitabinePhase 1Advanced Chronic Myeloid LeukemiaOncologyJan 2027
NCT04340843DecitabinePhase 2Locally Advanced Unresectable Primary Central ChondrosarcomaOncologyJan 2027
NCT05038592DecitabinePhase 1Chronic Myelomonocytic LeukemiaOncologyJan 2027
NCT01627041DecitabinePhase 2Acute Myeloid LeukemiaOncologyFeb 2027
NCT05396859DecitabinePhase 1Acute Myeloid LeukemiaOncologyFeb 2027
NCT00095784DecitabinePhase 2Primary MyelofibrosisOncologyFeb 2027
NCT04375631DecitabinePhase 1Recurrent Acute Myeloid LeukemiaOncologyFeb 2027
NCT03875287DecitabinePhase 1Solid TumorOncologyMar 2027
NCT05222984DecitabinePhase 1Recurrent Acute Myeloid LeukemiaOncologyMar 2027
NCT06156579DecitabinePhase 2AMLOncologyMar 2027
NCT05184842DecitabinePhase 2Myelodysplastic SyndromesOncologyMar 2027
NCT06327685DecitabinePhase 1Systemic Mastocytosis With an Associated Hematologic NeoplasmOncologyMar 2027
NCT06327685DecitabinePhase 1Systemic Mastocytosis With an Associated Hematologic NeoplasmOncologyMar 2027
NCT06129734DecitabinePhase 1Myeloid MalignancyOncologyMar 2027
NCT01861314DecitabinePhase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT02957968DecitabinePhase 2Breast AdenocarcinomaOncologyMar 2027
NCT07012044DecitabinePhase 1Acute Myeloid Leukemia Post Cytotoxic TherapyOncologyMar 2027
NCT06393985DecitabinePhase 2B-cell Acute Lymphoblastic LeukemiaOncologyApr 2027
NCT03586609DecitabinePhase 2Acute Myeloid LeukemiaOncologyApr 2027
NCT04975919DecitabinePhase 2Recurrent Acute Biphenotypic LeukemiaOncologyMay 2027
NCT06393361DecitabinePhase 2Ineligible Or Refused Transplant Patients With Classical Hodgkin LymphomaOncologyJun 2027
NCT03164057DecitabinePhase 2Acute Myeloid LeukemiaOncologyJun 2027
NCT05272384DecitabinePhase 1Recurrent B-Cell Non-Hodgkin LymphomaOncologyJun 2027
NCT00412594DecitabinePhase 2Hairy Cell LeukemiaOncologyJun 2027
NCT06827899DecitabinePhase 2Acute Myeloid LeukemiaOncologyJun 2027
NCT05961644DecitabinePhase 2Multiple Sclerosis, Secondary ProgressiveNeurologyJun 2027
NCT06445959DecitabinePhase 1Mutant IDH1 Inhibitor OlutasidenibOtherJun 2027
NCT06445959DecitabinePhase 1Mutant IDH1 Inhibitor OlutasidenibOtherJun 2027
NCT03041688DecitabinePhase 1Acute Myeloid LeukemiaOncologyJun 2027
NCT07172204DecitabinePhase 2Intensive Chemotherapy UnfitOncologyJul 2027
NCT06536959DecitabinePhase 2Relapsed Acute Myeloid LeukemiaOncologyJul 2027
NCT06532552DecitabinePhase 2Acute Myeloid Leukemia, AdultOncologyAug 2027
NCT02890329DecitabinePhase 1Previously Treated Myelodysplastic SyndromeOncologyAug 2027
NCT05600894DecitabinePhase 2Chronic Myelomonocytic LeukemiaOncologyAug 2027
NCT06712121DecitabinePhase 2T Lymphoblastic Leukemia/LymphomaOncologyAug 2027
NCT06511882DecitabinePhase 2Acute Myeloid LeukemiaOncologyOct 2027
NCT06232655DecitabinePhase 2Acute Myeloid LeukemiaOncologyOct 2027
NCT06923488DecitabinePhase 1Myelodysplastic SyndromesHematologyOct 2027

The 60 nearest readouts of 105 trials; the rest in the app.

Targets

DNMT3A (1) DNMT1 (1)

Companies with the same targets

Taiho Oncology AbbVie Bristol-Myers Squibb Otsuka Taiho Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.